Last reviewed · How we verify
NCT04220788
Pharmacist Enhanced Service for Cardiovascular Risk Reduction
NA trial testing Enhanced pharmacist service in Cardiovascular Risk Factor. Withdrawn.
31 December 2022
Quick facts
| Lead sponsor | Monash University |
|---|---|
| Phase | NA |
| Status | Withdrawn |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | sequential |
| Masking | double |
| Primary purpose | health services research |
| Start date | 1 March 2020 |
| Primary completion | 31 December 2022 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across Malaysia |
Drugs / interventions tested
- Enhanced pharmacist service
- Usual care
Conditions studied
- Cardiovascular Risk Factor — all drugs for Cardiovascular Risk Factor →
Sponsor
Monash University
Who can join
18 and older, any sex, with Cardiovascular Risk Factor. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Pharmacist services such as medication review, counselling and treatment adherence clinics can improve clinical, health related quality of life and economic outcomes. To prove this hypothesis a step-wedge, cluster randomized controlled trial will be held in primary care centers of the public health system of Malaysia. Participants who have a high risk of cardiovascular risk factors currently seeking care in primary care will be recruited. Control group will receive usual care and the intervention arm will be seen by a pharmacist prior to their follow-up, with a comprehensive medication review, counselling and dietary advice consultations every month for three months. Participating pharmacist will be trained in cardiovascular prevention pharmacotherapy, interview skills, educational techniques, and develop personalized plan for every participant. The investigators plan to randomize up to 2100 participants who are currently receiving care in the primary care clinics in the district of Petaling by modifying the current workflow in primary care, whereby the investigators aim to get participants who are at high risk to undergo counselling as well as a medication review with proper pharmaceutical care delivered to them prior to seeking their medical doctor to receive care.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04220788
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Cardiovascular Risk Factor
Currently open trials in the same condition.
- NCT07268781 — Impact of Golden Rice-Piper Crocatum Cookies on Lipid Control in Diabetes Mellitus Patients · NA · active not recruiting
- NCT06225544 — Lumasiran in Hyperoxalaemic Patients on Haemodialysis · Phase 2 · recruiting
- NCT06372054 — TORNADO-Omics Techniques and Neural Networks for the Development of Predictive Risk Models · recruiting
- NCT05887622 — The Potassium Supplementation Study · NA · recruiting
- NCT04962061 — A Combined Multidomain Intervention to Prevent Cognitive Decline Associated With Cardiovascular Risk Factors. · NA · recruiting
Other Monash University trials
Trials by the same sponsor.
- NCT07428473 — A Study of STX-1150 in Participants With Elevated Low-Density Lipoprotein Cholesterol (LDL-C) · Phase 1 · not yet recruiting
- NCT07300254 — Treponemal Shedding, Load, and Viability, in Women and Men-who-have-sex-with-women-only With Early Infectious Syphilis: · recruiting
- NCT06960967 — Effects of Chestnuts on Postprandial Glycaemic Response · NA · active not recruiting
- NCT07202078 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy: Starting Immunoglobulin (Start Ig) · Phase 2, PHASE3 · recruiting
- NCT07202091 — Role of Antibiotic Therapy or Immunoglobulin On iNfections in hAematoLogy Immunoglobulin Stopping or Extension (Stop Ig) · Phase 2, PHASE3 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04220788 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Monash University
- Last refreshed: 2 September 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04220788.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing